Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.38 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1848217 | 1.00 | PTGS2 (0.40) | PTGS2EPAS1PTGS1KDM4EMT-CO1 | |
| SCHEMBL21469773 | 0.84 | ENPP2 (0.39) | PTGS2 | |
| SCHEMBL30633576 | 0.84 | ENPP2 (0.39) | PTGS2 | |
| SCHEMBL776672 | 0.84 | PTGS2 (0.45) | PTGS2PTGS1 | |
| SCHEMBL17331447 | 0.78 | CA2 (0.52) | PTGS2PTGS1CYP2C19 | |
| SCHEMBL31367742 | 0.78 | ALDH1A1 (0.34) | HSD17B10 | |
| SCHEMBL17331594 | 0.78 | ALDH1A1 (0.34) | HSD17B10 | |
| SCHEMBL30633558 | 0.78 | GBA1 (0.43) | KDM4E | |
| SCHEMBL15352992 | 0.78 | FFAR4 (0.32) | EPAS1 | |
| SCHEMBL1510778 | 0.78 | GAA (0.39) | PTGS2EPAS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| CN-119101069-A | Spiro compounds and uses thereof | 轩竹生物科技股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-117916239-A | 3-Substituted 1H-pyrrolo [2,3-b ] pyridines as GRK5 modulators | 利德探索中心股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117157072-A | Novel cyclopento [ c ] pyrrole NR2B negative allosteric modulators | 诺华股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117043162-A | TYK2 selective inhibitors and uses thereof | 迈巴制药(南京)有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | PTGS2 3634/4885EPAS1 3750/4885PTGS1 2744/4885 |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | PTGS2 2455/4885EPAS1 3766/4885PTGS1 1684/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | PTGS2 2320/4885EPAS1 3804/4885PTGS1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.